Identification of biomarkers, pathways and therapeutic targets for EGFR-TKI resistance in NSCLC

leilei zhu, Shanshan Gao, Xianya Zhao, and Ying Wang
DOI: https://doi.org/10.26508/lsa.202302110

Corresponding author(s): Ying Wang, Anhui province Children Hospital

Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

June 15, 2023

Re: Life Science Alliance manuscript #LSA-2023-02110-T

Ying Wang
Anhui Children's Hospital

Dear Dr. Wang,

Thank you for submitting your manuscript entitled "Identification of biomarkers, pathways and potential therapeutic targets for EGFR-TKI resistance in non-small-cell lung cancer" to Life Science Alliance. The manuscript was assessed by an expert reviewer, whose comment is appended to this letter. We invite you to submit a revised manuscript addressing all the Reviewer comments.

To upload the revised version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex

You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

While you are revising your manuscript, please also attend to the below editorial points to help expedite the publication of your manuscript. Please direct any editorial questions to the journal office.

The typical timeframe for revisions is three months. Please note that papers are generally considered through only one revision cycle, so strong support from the referees on the revised version is needed for acceptance.

When submitting the revision, please include a letter addressing the reviewers' comments point by point.

We hope that the comments below will prove constructive as your work progresses.

Thank you for this interesting contribution to Life Science Alliance. We are looking forward to receiving your revised manuscript.

Sincerely,

Novella Guidi, PhD
Scientific Editor
Life Science Alliance

A. THESE ITEMS ARE REQUIRED FOR REVISIONS

-- A letter addressing the reviewers' comments point by point.

-- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).

-- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors

-- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title and running title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

-- By submitting a revision, you attest that you are aware of our payment policies found here: https://www.life-science-alliance.org/copyright-license-fee

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and

spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

IMPORTANT: It is Life Science Alliance policy that if requested, original data images must be made available. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original microscopy and blot data images before submitting your revision.

Reviewer #1 (Comments to the Authors (Required)):

The paper discussing EGFR-TKI resistance in lung cancer demonstrates the use of relevant models and sequencing data analysis to identify potential markers, investigate associated pathways, and explore sensitive targets. While the study provides valuable insights, it would benefit from more detailed bioinformatics analysis methods and additional experimental verification to strengthen its findings and provide robust evidence.
Major concerns:
1. Please clarify whether the data mentioned in the text refers to GSE64427 or GSE64472 to avoid confusion throughout the entire paper.

2. Figure 1c and d display data from two resistance groups and three sensitive groups from GSE64472, as well as two sensitive groups and one resistance group from GSE130160. However, the rationale behind this selection and the basis for these choices should be further explained. In fact, there are more groups in GSE64472 or GSE130160.

3. In order to identify genes most strongly associated with prognosis, the authors performed prognostic analysis after identifying hub genes related to TKI resistance. However, it is not clear why Disease-Free Survival (DFS) was used instead of Overall Survival (OS). Additionally, in Figure 3, although the P value of ITGAM is less than 0.05, the survival curves of the two groups with high or low expression of ITGAM are not completely separated. Can you explain it?

4. It is suggested to modify some graphics and statements to improve readability.

5. It is suggested to increase experimental verification of hub genes related to TKI resistance, such as drug sensitivity detection, etc.

Minor concerns:
Additional English language editing would be beneficial to this manuscript.

Dear Editors and Reviewer

   Thank you for your letter and for the reviewer's comments concerning our manuscript entitled "Identification of biomarkers, pathways and potential therapeutic targets for EGFR-TKI resistance in non-small-cell lung cancer"(LSA-2023-02110-T). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer's comments are as flowing:

   Responds to the reviewer's comments

Reviewer #1 (Comments to the Authors (Required)):

The paper discussing EGFR-TKI resistance in lung cancer demonstrates the use of relevant models and sequencing data analysis to identify potential markers, investigate associated pathways, and explore sensitive targets. While the study provides valuable insights, it would benefit from more detailed bioinformatics analysis methods and additional experimental verification to strengthen its findings and provide robust evidence.

Major concerns:

1. Please clarify whether the data mentioned in the text refers to GSE64427 or GSE64472 to avoid confusion throughout the entire paper.

2. Figure 1c and d display data from two resistance groups and three sensitive groups from GSE64472, as well as two sensitive groups and one resistance group from GSE130160. However, the rationale behind this selection and the basis for these choices should be further explained. In fact, there are more groups in GSE64472 or GSE130160.

3. In order to identify genes most strongly associated with prognosis, the authors performed prognostic analysis after identifying hub genes related to TKI resistance. However, it is not clear why Disease-Free Survival (DFS) was used instead of Overall Survival (OS). Additionally, in Figure 3, although the P value of ITGAM is less than 0.05, the survival curves of the two groups with high or low expression of ITGAM are not completely separated. Can you explain it?

4. It is suggested to modify some graphics and statements to improve readability.

5. It is suggested to increase experimental verification of hub genes related to TKI resistance, such as drug sensitivity detection, etc.

Reviewers' comments:
Reviewer #1 (Comments to the Authors (Required)):

The paper discussing EGFR-TKI resistance in lung cancer demonstrates the use of relevant models and sequencing data analysis to identify potential markers, investigate associated pathways, and explore sensitive targets. While the study provides valuable insights, it would benefit from more detailed bioinformatics analysis methods and additional experimental verification to strengthen its findings and provide robust evidence.

Author response: Thank you. We appreciate your comments and suggestions.

1. Please clarify whether the data mentioned in the text refers to GSE64427 or GSE64472 to avoid confusion throughout the entire paper.

Author response: Thank you. We apologize for causing confusion. We have revised the confusion "64427" has been replaced by "64472" in the revised manuscript.

2. Figure 1c and d display data from two resistance groups and three sensitive groups from GSE64472, as well as two sensitive groups and one resistance group from GSE130160. However, the rationale behind this selection and the basis for thse choices should be further explained. In fact, there are more groups in GSE64472 or GSE130160.

Author response: Thank you. We appreciate this comment. We appreciate your interest in the sources of sample, and thank you for your kind suggestion. We apologize for causing confusion. In the studies, our description of human data selection not sufficiently clear.Our study investigates the mechanism of drug resistance in the application of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients.Histological analyses revealed that PDXs showed a histology similar to that of patients' surgically resected tumors (SRTs), In order to make the results more reliable, we collected samples of Patient derived xenograft (PDX) models as the research subjects . In the GSE130160 study, they successfully established ten PDXs, including three adenocarcinoma (AD), six squamous cell carcinoma (SQ) and one large cell carcinoma (LA), from 30 patients with non-small cell lung cancer (NSCLC) (18 AD, 10 SQ, and 2 LA), mainly in SHO mice (Crlj:SHO-PrkdcscidHrhr). Two out of three PDXs with AD histology had EGFR mutations (L858R or exon19 deletion) and were sensitive to EGFR tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib and osimertinib. Fortunately, in one of the two PDXs with an EGFR mutation, osimertinib resistance was induced that was associated with epithelial-to-mesenchymal transition.Therefore, we included these two sensitive samples with the EGFR mutation, and one drug-resistant sample for subsequent research. In the GSE64472 study, they successfully established three PDXs of human NSCLC, Overall design Murine models of human NSCLC were generated and targeted inhibition studies were performed using AZD2171 (cediranib) and ZD6474 (vandetanib). Cediranib is a TKI through the VEGFR mechanism, while vandetanib is a TKI that acts on both EGFR and VEGFR pathways. We selected three vandetanib sensitive samples and two drug-resistant samples from the GSE64472 study for our subsequent research.Thank you very much for your understanding and support.

1. In order to identify genes most strongly associated with prognosis, the authors performed prognostic analysis after identifying hub genes related to TKI resistance. However, it is not clear why Disease-Free Survival (DFS) was used instead of Overall Survival (OS)

Author response: Thank you for your insightful suggestion. We apologize for causing confusion. At present, tyrosine kinase inhibitor (TKI) treatment is the first-line therapy

for some tumors. Acquired resistance represents a bottleneck to molecularly targeted therapies such as epidermal growth factor receptor (EGFR) TKI treatment in lung cancer. A deeper understanding of resistance mechanisms can provide insights into this phenomenon and help to develop additional therapeutic strategies to overcome or delay resistance.The manifestation of drug resistance in tumors is tumor growth and metastasis.The clinical manifestation is the progression and deterioration of the disease. Disease-free survival (DFS), refers to the time from randomization to disease recurrence or death due to disease progression.For the above considerations, we chose DFS instead of OS as the prognostic observation indicator.Thank you very much for your understanding and support.

Additionally, in Figure 3, although the P value of ITGAM is less than 0.05, the survival curves of the two groups with high or low expression of ITGAM are not completely separated. Can you explain it?

Author response: Thank you for your insightful suggestion. In this study, We used the Kaplan–Meier Plotter database to explore how these hub genes were related to NSCLC patient DFS, with data sourced from GEO, TGA, and TCGA.Due to the fact that the cases come from different studies, the follow-up time of the cases (after the cut-off point) varies. For this reason, the survival curves of the two groups with high or low expression of ITGAM intersect at the end.Thank you very much for your understanding and support.

4. It is suggested to modify some graphics and statements to improve readability.

Author response: Thank you very much for this valuable suggestion. The sentences in the main text have been modified to improve readability.Thank you very much for your understanding and support.

5. It is suggested to increase experimental verification of hub genes related to TKI resistance, such as drug sensitivity detection, etc.

Author response: Thank you for this valuable suggestion. Because of the time constraints, we have not conducted further experimental verification, and hope that you can understand our position and support our current inability to proceed.We appreciate this important point from the reviewer and have provided additional discussion relating to this point (see Discussion, Page 9, Line 257-261).Thank you very much for your understanding and support.

Minor concerns:
Additional English language editing would be beneficial to this manuscript.

Author response: Thank you for this valuable suggestion. This manuscript has been language edited by Elsevier Language Editing Service. Thank you very much for your understanding and support.

September 20, 2023

RE: Life Science Alliance Manuscript #LSA-2023-02110-TR

Ms. Ying Wang
Anhui province Children Hospital
39 Wangjiang East Road, Baohe District, Hefei City, Anhui Province
Hefei 230001
China

Dear Dr. Wang,

Thank you for submitting your revised manuscript entitled "Identification of biomarkers, pathways and therapeutic targets for EGFR-TKI resistance in NSCLC". We would be happy to publish your paper in Life Science Alliance pending final revisions necessary to meet our formatting guidelines.

Along with points mentioned below, please tend to the following:
-please upload your figures as single files
-please remove your figures from the main manuscript file
-please add an Abstract and a Summary Blurb/Alternate Abstract to our system
-please note that the abstract should be a single paragraph not exceeding 175 words
-please add a Category for your manuscript in our system
-please add the Twitter handle of your host institute/organization as well as your own or/and one of the authors in our system
-please note that the titles in the system and on the manuscript file must match
-please place your figure legends after the reference section
-figure 4 is wrongly labeled as Figure 3; please correct
-please incorporate any points from the Conclusion section into the Discussion; we only allow a Discussion section

If you are planning a press release on your work, please inform us immediately to allow informing our production team and scheduling a release date.

LSA now encourages authors to provide a 30-60 second video where the study is briefly explained. We will use these videos on social media to promote the published paper and the presenting author (for examples, see https://twitter.com/LSAjournal/timelines/1437405065917124608). Corresponding or first-authors are welcome to submit the video. Please submit only one video per manuscript. The video can be emailed to contact@life-science-alliance.org

To upload the final version of your manuscript, please log in to your account: https://lsa.msubmit.net/cgi-bin/main.plex
You will be guided to complete the submission of your revised manuscript and to fill in all necessary information. Please get in touch in case you do not know or remember your login name.

To avoid unnecessary delays in the acceptance and publication of your paper, please read the following information carefully.

A. FINAL FILES:

These items are required for acceptance.

-- An editable version of the final text (.DOC or .DOCX) is needed for copyediting (no PDFs).

-- High-resolution figure, supplementary figure and video files uploaded as individual files: See our detailed guidelines for preparing your production-ready images, https://www.life-science-alliance.org/authors

-- Summary blurb (enter in submission system): A short text summarizing in a single sentence the study (max. 200 characters including spaces). This text is used in conjunction with the titles of papers, hence should be informative and complementary to the title. It should describe the context and significance of the findings for a general readership; it should be written in the present tense and refer to the work in the third person. Author names should not be mentioned.

B. MANUSCRIPT ORGANIZATION AND FORMATTING:

Full guidelines are available on our Instructions for Authors page, https://www.life-science-alliance.org/authors

We encourage our authors to provide original source data, particularly uncropped/-processed electrophoretic blots and

spreadsheets for the main figures of the manuscript. If you would like to add source data, we would welcome one PDF/Excel-file per figure for this information. These files will be linked online as supplementary "Source Data" files.

Submission of a paper that does not conform to Life Science Alliance guidelines will delay the acceptance of your manuscript.

It is Life Science Alliance policy that if requested, original data images must be made available to the editors. Failure to provide original images upon request will result in unavoidable delays in publication. Please ensure that you have access to all original data images prior to final submission.

The license to publish form must be signed before your manuscript can be sent to production. A link to the electronic license to publish form will be sent to the corresponding author only. Please take a moment to check your funder requirements.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

Thank you for your attention to these final processing requirements. Please revise and format the manuscript and upload materials within 7 days.

Thank you for this interesting contribution, we look forward to publishing your paper in Life Science Alliance.

Sincerely,

Eric Sawey, PhD
Executive Editor
Life Science Alliance
http://www.lsajournal.org

Reviewer #1 (Comments to the Authors (Required)):

I have no additional inquiries regarding the revised manuscript. The authors have satisfactorily addressed all of my previous questions.

September 28, 2023

RE: Life Science Alliance Manuscript #LSA-2023-02110-TRR

Ms. Ying Wang
Anhui province Children Hospital
39 Wangjiang East Road, Baohe District, Hefei City, Anhui Province
Hefei 230001
China

Dear Dr. Wang,

Thank you for submitting your Resource entitled "Identification of biomarkers, pathways and therapeutic targets for EGFR-TKI resistance in NSCLC". It is a pleasure to let you know that your manuscript is now accepted for publication in Life Science Alliance. Congratulations on this interesting work.

The final published version of your manuscript will be deposited by us to PubMed Central upon online publication.

Your manuscript will now progress through copyediting and proofing. It is journal policy that authors provide original data upon request.

Reviews, decision letters, and point-by-point responses associated with peer-review at Life Science Alliance will be published online, alongside the manuscript. If you do want to opt out of having the reviewer reports and your point-by-point responses displayed, please let us know immediately.

IMPORTANT: If you will be unreachable at any time, please provide us with the email address of an alternate author. Failure to respond to routine queries may lead to unavoidable delays in publication.

Scheduling details will be available from our production department. You will receive proofs shortly before the publication date. Only essential corrections can be made at the proof stage so if there are any minor final changes you wish to make to the manuscript, please let the journal office know now.

DISTRIBUTION OF MATERIALS:
Authors are required to distribute freely any materials used in experiments published in Life Science Alliance. Authors are encouraged to deposit materials used in their studies to the appropriate repositories for distribution to researchers.

You can contact the journal office with any questions, contact@life-science-alliance.org

Again, congratulations on a very nice paper. I hope you found the review process to be constructive and are pleased with how the manuscript was handled editorially. We look forward to future exciting submissions from your lab.

Sincerely,

Eric Sawey, PhD
Executive Editor
Life Science Alliance
http://www.lsajournal.org